Meriofert Pfs

Luteinising Hormone (Human), Follicle-Stimulating Hormone, the active ingredient in Meriofert Pfs, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It is employed in the management of infertility related to anovulation, assisted reproductive technologies such as IVF, and hypogonadotropic hypogonadism in both women and men.

GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide, ensuring quality assurance, traceability and adherence to EU regulatory standards through rigorous manufacturing and distribution processes.

Meriofert Pfs contains LH and FSH, gonadotropins that act on the reproductive endocrine axis.

- Infertility due to anovulation: stimulates follicular growth and ovulation to restore fertility. - Assisted reproductive technology (e.g., IVF): supports controlled ovarian stimulation for oocyte retrieval. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to induce gametogenesis and sex‑steroid production.

Adverse reactions may occur with any injectable gonadotropin preparation.

Common Side Effects: - Injection site pain or bruising. - Headache. - Mild abdominal discomfort. - Nausea.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS). - Thromboembolic events. - Allergic reactions including anaphylaxis. - Multiple pregnancy. - Persistent severe abdominal pain.

When using Meriofert Pfs, clinicians should observe several safety measures.

- Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Ovarian monitoring: perform serial ultrasound to detect hyperstimulation. - Thyroid function: assess in patients with known thyroid disorders. - Allergy: avoid in individuals with known hypersensitivity to gonadotropins. - Cancer history: use cautiously in estrogen‑sensitive malignancies. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may affect the efficacy or safety of Meriofert Pfs.

Major Interactions (Avoid): - GnRH antagonists: may blunt the intended gonadotropin response. - Oral contraceptives: suppress endogenous LH/FSH, reducing effectiveness. - High‑dose estrogen therapy: can antagonize gonadotropin action.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for thrombotic risk if OHSS develops. - Thyroid hormone replacement: dosage may need adjustment during treatment.